The Pathopharmacological Interplay between Vanadium and Iron in Parkinson’s Disease Models.

Ohiomokhare, Samuel; Olaolorun, Francis; Ladagu, Amany; Olopade, Funmilayo; Howes, Melanie-Jayne R.; Okello, Edward; Olopade, James; Chazot, Paul L.

The Pathopharmacological Interplay between Vanadium and Iron in Parkinson’s Disease Models.

Download

Name

ijms-21-06719.pdf

Description

visibility:open

Size

1.7 MB

Format

Adobe PDF

Checksum (CRC64NVME)

XGY/61BxRPU=

Resource type

Journal article

Creator (person)

Ohiomokhare, Samuel

ORCID

Olaolorun, Francis

ORCID

Ladagu, Amany

Olopade, Funmilayo

ORCID

Howes, Melanie-Jayne R.

Okello, Edward

Olopade, James

Chazot, Paul L.

Date published

September 14, 2020

Abstract

Parkinson’s disease (PD) pathology is characterised by distinct types of cellular defects, notably associated with oxidative damage and mitochondria dysfunction, leading to the selective loss of dopaminergic neurons in the brain’s substantia nigra pars compacta (SNpc). Exposure to some environmental toxicants and heavy metals has been associated with PD pathogenesis. Raised iron levels have also been consistently observed in the nigrostriatal pathway of PD cases. This study explored, for the first time, the effects of an exogenous environmental heavy metal (vanadium) and its interaction with iron, focusing on the subtoxic effects of these metals on PD-like oxidative stress phenotypes in Catecholaminergic a-differentiated (CAD) cells and PTEN-induced kinase 1 (PINK−1)B9Drosophila melanogaster models of PD. We found that undifferentiated CAD cells were more susceptible to vanadium exposure than differentiated cells, and this susceptibility was modulated by iron. In PINK−1 flies, the exposure to chronic low doses of vanadium exacerbated the existing motor deficits, reduced survival, and increased the production of reactive oxygen species (ROS). Both Aloysia citrodora Paláu, a natural iron chelator, and Deferoxamine Mesylate (DFO), a synthetic iron chelator, significantly protected against the PD-like phenotypes in both models. These results favour the case for iron-chelation therapy as a viable option for the symptomatic treatment of PD.